Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,332
Total Claims
$2.1M
Drug Cost
449
Beneficiaries
$4,592
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
+291%
Cost per patient vs peers
$4,592 vs $1,174 avg
+131%
Brand preference vs peers
20.5% vs 8.9% avg
Brand vs Generic
Brand: 1,891 claims · $1.9M
Generic: 7,340 claims · $162K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 140 | $155K |
| Sitagliptin Phos/Metformin Hcl | 138 | $144K |
| Linaclotide | 98 | $126K |
| Empagliflozin | 102 | $122K |
| Rivaroxaban | 91 | $114K |
| Adalimumab | 15 | $113K |
| Dapagliflozin Propanediol | 82 | $108K |
| Semaglutide | 88 | $108K |
| Insulin Glargine,hum.Rec.Anlog | 118 | $80K |
| Empaglifloz/Linaglip/Metformin | 84 | $73K |
| Apixaban | 53 | $69K |
| Dulaglutide | 55 | $68K |
| Insulin Detemir | 49 | $54K |
| Apremilast | 11 | $54K |
| Linagliptin | 50 | $51K |
Prescribing Profile
Patient Profile
69
Avg Age
64%
Female
1.50
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data